Guardant Health (GH): Among the Best Performing Mid Cap Stocks to Buy According to Analysts
We recently published a list of 10 Best Performing Mid Cap Stocks to Buy According to Analysts. In this article, we are going ...
Guardant Health price target raised to $50 from $34 at Piper Sandler
Piper Sandler analyst David Westenberg raised the firm’s price target on Guardant Health (GH) to $50 from $34 following quarterly results. The ...
Piper Sandler Keeps Their Buy Rating on Guardant Health (GH)
In a report released today, David Westenberg from Piper Sandler maintained a Buy rating on Guardant Health (GH – Research Report), with a price ...
manilatimes16h
Liquid Biopsy Market Worth US$11.3 billion at a robust CAGR of 11.9% | MarketsandMarkets™.
The global Liquid Biopsy Market, valued at US$5.9 billion in 2023, is forecasted to grow at a robust CAGR of 11.9%, reaching ...
Tumor Profiling Market Projected to Surpass USD 24.8 Billion by 2032, Driven by Advancements in Precision Oncology – SNS Insider
SNS Insider Report Highlights 10.04% CAGR Growth Fueled by Technological Breakthroughs and Rising Global Cancer Burden.Pune, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Tumor Profiling Market Size & Growth ...
10 Best Performing Mid Cap Stocks to Buy According to Analysts
Simeon Hyman, Global Investment Strategist at ProShares Advisors, appeared on CNBC to discuss the upcoming jobs report and its expected impact on the market.